CTOs on the Move

GT Biopharma

www.gtbiopharma.com

 
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute lymphocytic leukemia, non-Hodgkin`s lymphoma, acute myeloid leukemia and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE™) platform technology.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

GT Biopharma raised $23.7M on 02/06/2021

Similar Companies

Sequenom

Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.

Nanosphere

Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its name.

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nuvalent

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs.

Vaxxinity

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health.